ArticlePloS one2025
Predicting podoplanin expression and prognostic significance in high-grade glioma based on TCGA TCIA radiomics.
Article in PloS one, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Exploring the dual role of extracellular vesicles in coagulation and immune modulation in glioblastoma.Scientific reports · 2026Article
- Integrated single-cell and multi-cohort analyses reveal CTCF as a key regulator of chemo-immunotherapy resistance in lung adenocarcinoma.Frontiers in cell and developmental biology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundPodoplanin (PDPN) is a membrane glycoprotein implicated in tumor invasion and immune modulation in high-grade gliomas (HGGs). However, the non-invasive prediction of PDPN expression and its prognostic significance using radiomics remains unexplored. MATERIALS AND
methodsThis study used preoperative contrast-enhanced MRI T1WI data analyzed by gradient boosting machine to predict podoplanin (PDPN) expression and overall survival (OS) in HGG patients.
resultsWe retrospectively analyzed 89 HGG patients' clinical data, MRI images, and RNA-seq profiles from TCIA. For each patient, 107 radiomics features were extracted from HGG subregions. The radiomics prognostic model was built using two selected features, glcm_Idmn and glcn_Idn. Through validation with external the REMBRANDT dataset (n=39), the model demonstrated great predictive performance for the PDPN expression levels and OS in HGG. The area under the curve of the ROC in the radiomics signature combined with clinical risk factors for the 1-year, 2-year, and 3-year OS rates in the TCIA-HGG were 0.799, 0.883, and 0.923, respectively. Gradient boosting machine using preoperative MRI T1WI and extracted radiomics features performed well in predicting the expression of PDPN and OS in HGG.
conclusionsRadiomics features extracted from MRI images can non-invasively predict PDPN expression and prognosis in HGG, offering a potential imaging biomarker for individualized clinical management.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.